secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biofrontera Inc. (BFRI)
CIK:        0001858685
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001493152-24-045205
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biofrontera Q3 revenue $9.0M (+1.5% YoY); net loss narrows; FDA approves higher Ameluz dosage
--------------------------------------------------------------------------------

- Total Q3 2024 revenue $9.0M, up 1.5% YoY (would have been +19% without Hurricane Milton delays of ~$1.5M).
- Net loss narrowed to $5.7M from $6.3M YoY; adjusted EBITDA -$4.6M vs -$3.9M.
- FDA approved sNDA on Oct 4 to increase max Ameluz dosage from one to three tubes per treatment.
- Phase 3 sBCC study met all endpoints: 75.9% histological clearance vs 19% placebo (p<0.0001); FDA filing expected H1 2025.
- Cash and equivalents $2.9M at Sep 30, up from $1.3M at Dec 31, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858685/000149315224045205/0001493152-24-045205-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858685/000149315224045205/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-045205

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer